SCHEMBL1966018

SCHEMBL1966018

CCOC(=O)c1c(O)c2cccn2n(Cc2cccc(F)c2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
GLA P06280 1/20 0.49
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 5/20 0.44
PTGES O14684 1/20 0.44
ALOX5 P09917 1/20 0.44
RECQL P46063 1/20 0.42
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
FEN1 P39748 1/20 0.40
TP53 P04637 1/20 0.40
USP2 O75604 1/20 0.40
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965910 0.89 ALDH1A1 (0.47) LMNAALDH1A1KDM4EALOX5RECQL
SCHEMBL1966103 0.88 KMT2A (0.50) LMNAALDH1A1KDM4EPTGESALOX5
SCHEMBL1966458 0.87 KDM4E (0.46) ALDH1A1KDM4ERECQLMEN1HPGD
SCHEMBL1967350 0.87 KDM4E (0.54) LMNAGLAALDH1A1KDM4ERECQL
SCHEMBL1968973 0.85 ALDH1A1 (0.43) LMNAALDH1A1KDM4EALOX5RECQL
SCHEMBL1966882 0.84 ALDH1A1 (0.46) LMNAALDH1A1KDM4EPTGESALOX5
SCHEMBL1968371 0.84 KDM4E (0.47) LMNAGLAALDH1A1KDM4ERECQL
SCHEMBL1967127 0.83 KDM4E (0.48) LMNAALDH1A1KDM4EPTGESALOX5
SCHEMBL1966099 0.82 KDM4E (0.44) LMNAALDH1A1KDM4EALOX5RECQL
SCHEMBL1966096 0.81 FEN1 (0.53) LMNAGLAALDH1A1KDM4EALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 LMNA 3079/4885GLA 715/4885ALDH1A1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.